ATE366121T1 - Systemische verabreichung von serum-stabilen plasmid-lipid partikeln zur krebstherapie - Google Patents
Systemische verabreichung von serum-stabilen plasmid-lipid partikeln zur krebstherapieInfo
- Publication number
- ATE366121T1 ATE366121T1 AT99903557T AT99903557T ATE366121T1 AT E366121 T1 ATE366121 T1 AT E366121T1 AT 99903557 T AT99903557 T AT 99903557T AT 99903557 T AT99903557 T AT 99903557T AT E366121 T1 ATE366121 T1 AT E366121T1
- Authority
- AT
- Austria
- Prior art keywords
- serum
- cancer therapy
- systemic administration
- lipid particles
- stable plasmid
- Prior art date
Links
- 238000011275 oncology therapy Methods 0.000 title 1
- 239000002245 particle Substances 0.000 title 1
- 238000007910 systemic administration Methods 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000009826 neoplastic cell growth Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7359898P | 1998-02-03 | 1998-02-03 | |
| US8691798P | 1998-05-27 | 1998-05-27 | |
| US10142998P | 1998-09-22 | 1998-09-22 | |
| US11238498P | 1998-12-14 | 1998-12-14 | |
| US24310299A | 1999-02-02 | 1999-02-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE366121T1 true ATE366121T1 (de) | 2007-07-15 |
Family
ID=27535971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99903557T ATE366121T1 (de) | 1998-02-03 | 1999-02-03 | Systemische verabreichung von serum-stabilen plasmid-lipid partikeln zur krebstherapie |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1053023B2 (de) |
| JP (1) | JP2002502831A (de) |
| AT (1) | ATE366121T1 (de) |
| AU (1) | AU749881B2 (de) |
| CA (2) | CA2319468A1 (de) |
| DE (1) | DE69936444T3 (de) |
| WO (2) | WO1999039741A2 (de) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE443528T1 (de) | 1998-01-05 | 2009-10-15 | Univ Washington | Erhöhter transport unter benutzung membranzerstörender stoffe |
| WO2002100431A1 (en) * | 2001-06-08 | 2002-12-19 | The Forth Military Medical University | A pharmaceutical kit comprising anti-human seminal plasma protein single chain antibody/human carboxypeptidase fusion protein and prodrug |
| CA2469623C (en) | 2001-12-12 | 2012-05-29 | F H Faulding & Co Limited | Composition for the preservation of viruses |
| AU2003239368A1 (en) | 2002-05-06 | 2003-11-17 | Board Of Regents, The University Of Texas System | Targeting proteins to deliver therapeutic or diagnostic reagents |
| CA3029724A1 (en) | 2008-11-10 | 2010-05-14 | Muthiah Manoharan | Lipids and compositions for the delivery of therapeutics |
| DK3532103T3 (da) | 2016-10-26 | 2026-03-02 | Acuitas Therapeutics Inc | Formuleringer af lipid-nanopartikler |
| US11338045B2 (en) | 2017-03-17 | 2022-05-24 | Newcastle University | Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy |
| WO2018191719A1 (en) | 2017-04-13 | 2018-10-18 | Acuitas Therapeutics, Inc. | Lipid delivery of therapeutic agents to adipose tissue |
| WO2019089828A1 (en) | 2017-10-31 | 2019-05-09 | Acuitas Therapeutics, Inc. | Lamellar lipid nanoparticles |
| DK3807413T3 (da) | 2018-06-18 | 2025-08-25 | Res Inst Nationwide Childrens Hospital | Adenoassocieret virusvektorfremføring af muskelspecifik mikrodystrofin til behandling af muskeldystrofi |
| CA3113449A1 (en) | 2018-09-21 | 2020-03-26 | Acuitas Therapeutics, Inc. | Systems and methods for manufacturing lipid nanoparticles and liposomes |
| UA129330C2 (uk) | 2019-08-14 | 2025-03-19 | Акітас Терап'Ютікс, Інк. | Поліпшені ліпідні наночастинки для доставляння нуклеїнових кислот |
| AU2021250814A1 (en) | 2020-03-30 | 2022-10-13 | BioNTech SE | RNA compositions targeting Claudin-18.2 |
| MX2022016332A (es) | 2020-06-15 | 2023-04-03 | Res Inst Nationwide Childrens Hospital | Administracion de vectores de virus adenoasociados para distrofias musculares. |
| WO2025056938A1 (en) | 2023-09-11 | 2025-03-20 | BioNTech SE | Rna compositions for delivery of incretin agents |
| DK4319803T3 (da) | 2021-04-08 | 2025-12-15 | Vaxthera Sas | Coronavirusvaccine omfattende et mosaikprotein |
| WO2023023055A1 (en) | 2021-08-16 | 2023-02-23 | Renagade Therapeutics Management Inc. | Compositions and methods for optimizing tropism of delivery systems for rna |
| TW202328067A (zh) | 2021-09-14 | 2023-07-16 | 美商雷納嘉德醫療管理公司 | 環狀脂質及其使用方法 |
| CN118317944A (zh) | 2021-09-14 | 2024-07-09 | 雷纳嘉德医疗管理公司 | 非环状脂质及其使用方法 |
| US20250043269A1 (en) | 2021-11-03 | 2025-02-06 | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad | Precise Genome Editing Using Retrons |
| CN118829625A (zh) | 2021-11-16 | 2024-10-22 | 赛欧生物医药股份有限公司 | 新型可电离脂质和脂质纳米颗粒以及它们的使用方法 |
| MX2024006134A (es) | 2021-11-22 | 2024-07-29 | Sail Biomedicines Inc | Lipidos ionizables novedosos y nanoparticulas de lipido y metodos para usar los mismos. |
| WO2023122752A1 (en) | 2021-12-23 | 2023-06-29 | Renagade Therapeutics Management Inc. | Constrained lipids and methods of use thereof |
| WO2023141602A2 (en) | 2022-01-21 | 2023-07-27 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
| IL314324A (en) | 2022-01-27 | 2024-09-01 | BioNTech SE | Pharmaceutical preparations for administration of herpes simplex virus antigens and related methods |
| CA3245624A1 (en) | 2022-03-25 | 2023-09-28 | Sail Biomedicines, Inc. | NEW IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND THEIR METHODS OF USE |
| AU2023251104A1 (en) | 2022-04-07 | 2024-10-17 | Renagade Therapeutics Management Inc. | Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents |
| EP4522650A1 (de) | 2022-05-13 | 2025-03-19 | BioNTech SE | Gegen hiv gerichtete rna-zusammensetzungen |
| WO2023230295A1 (en) | 2022-05-25 | 2023-11-30 | BioNTech SE | Rna compositions for delivery of monkeypox antigens and related methods |
| EP4518845A1 (de) | 2022-05-30 | 2025-03-12 | BioNTech SE | Komplexe zur verabreichung von nukleinsäuren |
| KR20250056256A (ko) | 2022-08-31 | 2025-04-25 | 세일 바이오메디슨스, 인크. | 신규 이온화성 지질 및 지질 나노입자, 그리고 이의 사용 방법 |
| WO2024063788A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of malaria antigens and related methods |
| WO2024063789A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of malaria antigens and related methods |
| EP4590331A1 (de) | 2022-09-23 | 2025-07-30 | BioNTech SE | Zusammensetzungen zur abgabe von plasmodium-csp-antigenen und zugehörige verfahren |
| CA3267942A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | COMPOSITIONS FOR THE ADMINISTRATION OF HEPATIC STAGE ANTIGENS AND ASSOCIATED METHODS |
| IL319682A (en) | 2022-10-06 | 2025-05-01 | BioNTech SE | RNA complexes targeting claudin-18.2 |
| WO2024074211A1 (en) | 2022-10-06 | 2024-04-11 | BioNTech SE | Rna compositions targeting claudin-18.2 |
| WO2024141955A1 (en) | 2022-12-28 | 2024-07-04 | BioNTech SE | Rna compositions targeting hiv |
| WO2024228044A1 (en) | 2023-05-03 | 2024-11-07 | BioNTech SE | Optimized csp variants and related methods |
| WO2024229309A2 (en) | 2023-05-03 | 2024-11-07 | Manifold Biotechnologies, Inc. | Methodsand compositions for high-throughput protein delivery, screening, and detection |
| WO2024228150A1 (en) | 2023-05-03 | 2024-11-07 | BioNTech SE | Optimized csp variants and related methods |
| WO2025024335A2 (en) | 2023-07-21 | 2025-01-30 | BioNTech SE | Compositions for delivery of plasmodium antigens and related methods |
| WO2025024324A1 (en) | 2023-07-21 | 2025-01-30 | BioNTech SE | Compositions for delivery of plasmodium antigens and related methods |
| WO2025024337A1 (en) | 2023-07-24 | 2025-01-30 | BioNTech SE | Compositions for delivery of plasmodium antigens and related methods |
| WO2025026545A1 (en) | 2023-08-01 | 2025-02-06 | BioNTech SE | Ionizable thioplipids and uses thereof |
| TW202519509A (zh) | 2023-08-01 | 2025-05-16 | 德商拜恩技術股份公司 | 可離子化硫脂質及其用途 |
| WO2025027579A2 (en) | 2023-08-03 | 2025-02-06 | BioNTech SE | Rna compositions targeting hiv |
| WO2025027576A2 (en) | 2023-08-03 | 2025-02-06 | BioNTech SE | Rna compositions targeting hiv |
| WO2025030154A1 (en) | 2023-08-03 | 2025-02-06 | The Trustees Of The University Of Pennsylvania | Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods |
| WO2025030097A2 (en) | 2023-08-03 | 2025-02-06 | BioNTech SE | Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods |
| WO2025054556A1 (en) | 2023-09-07 | 2025-03-13 | BioNTech SE | Rna compositions for delivery of mpox antigens and related methods |
| WO2025057088A1 (en) | 2023-09-11 | 2025-03-20 | BioNTech SE | Rna compositions for delivery of incretin agents |
| WO2025064850A1 (en) | 2023-09-22 | 2025-03-27 | BioNTech SE | Rna constructs with n-terminal degrons to enhance an immune response |
| WO2025081042A1 (en) | 2023-10-12 | 2025-04-17 | Renagade Therapeutics Management Inc. | Nickase-retron template-based precision editing system and methods of use |
| JP2025097909A (ja) | 2023-11-15 | 2025-07-01 | ビオンテック・ソシエタス・エウロパエア | Ｓａｒｓ－ｃｏｖ－２免疫原性組成物 |
| WO2025106754A1 (en) | 2023-11-15 | 2025-05-22 | BioNTech SE | Coronavirus vaccine |
| WO2025124711A1 (en) | 2023-12-13 | 2025-06-19 | BioNTech SE | Glycolipid compositions |
| WO2025133105A1 (en) | 2023-12-21 | 2025-06-26 | Biontech Delivery Technologies Gmbh | Compositions and methods |
| WO2025134066A1 (en) | 2023-12-21 | 2025-06-26 | Biontech Delivery Technologies Gmbh | Ionizable lipids |
| WO2025134062A2 (en) | 2023-12-21 | 2025-06-26 | Biontech Delivery Technologies Gmbh | Ionizable lipids |
| WO2025149492A1 (en) | 2024-01-08 | 2025-07-17 | BioNTech SE | Rna encoding an immune inhibitory il-1 family member |
| WO2025155753A2 (en) | 2024-01-17 | 2025-07-24 | Renagade Therapeutics Management Inc. | Improved gene editing system, guides, and methods |
| TW202543583A (zh) | 2024-03-01 | 2025-11-16 | 加拿大商阿奎特斯醫療公司 | 用於將治療劑包覆於脂質奈米顆粒中之材料及方法 |
| WO2025202937A1 (en) | 2024-03-26 | 2025-10-02 | BioNTech SE | Cancer vaccines |
| WO2025213131A1 (en) | 2024-04-05 | 2025-10-09 | BioNTech SE | Rna compositions for delivery of orthopox antigens and related methods |
| WO2025262460A1 (en) | 2024-06-21 | 2025-12-26 | BioNTech SE | Lipid compositions for nucleic acid delivery |
| WO2026015882A1 (en) | 2024-07-12 | 2026-01-15 | BioNTech SE | Hsv antigen fragments and related methods |
| WO2026018213A1 (en) | 2024-07-18 | 2026-01-22 | Vaxthera Sas | A broadly protective mosaic vaccine against highly pathogenic avian influenza viruses |
| WO2026020171A2 (en) | 2024-07-19 | 2026-01-22 | Aera Therapeutics, Inc. | Chimeric antigen receptor constructs |
| WO2026047603A1 (en) | 2024-08-28 | 2026-03-05 | BioNTech SE | Sars-cov-2 immunogenic compositions |
| WO2026057626A1 (en) | 2024-09-11 | 2026-03-19 | BioNTech SE | Peptidoglycan hydrolases having multiple enzymatically active domains |
| WO2026057625A1 (en) | 2024-09-11 | 2026-03-19 | BioNTech SE | Peptidoglycan hydrolases having a chap domain with engineered active site |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5676954A (en) | 1989-11-03 | 1997-10-14 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
| DE69031305T2 (de) * | 1989-11-03 | 1998-03-26 | Univ Vanderbilt | Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| WO1993012240A1 (en) | 1991-12-17 | 1993-06-24 | The Regents Of The University Of California | Gene therapy for cystic fibrosis transmembrane conductance regulator activity (cftr) |
| WO1993025673A1 (en) | 1992-06-04 | 1993-12-23 | The Regents Of The University Of California | In vivo gene therapy with intron-free sequence of interest |
| EP0714308A4 (de) * | 1993-08-26 | 1998-07-29 | Univ California | Methode, zusammensetzungen und vorrichtungen zur verabreichung von nackten polynukleotiden, welche für biologisch aktive peptide kodieren |
| US5631236A (en) * | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| HUT76095A (en) | 1994-04-26 | 1997-06-30 | Childrens Medical Center | Angiostatin and method of use for inhibition of angiogenesis |
| GB9415167D0 (en) | 1994-07-27 | 1994-09-14 | Springer Caroline J | Improvements relating to cancer therapy |
| GB9501052D0 (en) | 1995-01-19 | 1995-03-08 | Cancer Res Campaign Tech | Improvements relating to prodrugs |
| US7517858B1 (en) * | 1995-06-07 | 2009-04-14 | The Regents Of The University Of California | Prodrugs of pharmaceuticals with improved bioavailability |
| US5705385A (en) | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| ES2231819T3 (es) * | 1995-06-07 | 2005-05-16 | Inex Pharmaceuticals Corp | Particulas de lipido-acido nucleico preparadas a traves de un intermedio complejo de lipido-acido nucleico hidrofobo y uso para transferir genes. |
| GB9517001D0 (en) | 1995-08-18 | 1995-10-18 | Denny William | Enediyne compounds |
| BR9611174A (pt) | 1995-10-23 | 1999-09-14 | Childrens Medical Center | Proteína de endostatina isolada, e composições terapêuticas antiangiogénicas formadas com a mesma. |
| GB9523703D0 (en) | 1995-11-20 | 1996-01-24 | Wellcome Found | Enzyme prodrug thearapy |
| US6347397B1 (en) | 1999-03-29 | 2002-02-12 | International Business Machines Corporation | System, method, and program for providing an object-oriented install architecture |
| US8266598B2 (en) | 2008-05-05 | 2012-09-11 | Microsoft Corporation | Bounding resource consumption using abstract interpretation |
-
1999
- 1999-02-03 JP JP2000530238A patent/JP2002502831A/ja active Pending
- 1999-02-03 CA CA002319468A patent/CA2319468A1/en not_active Abandoned
- 1999-02-03 EP EP99903557A patent/EP1053023B2/de not_active Expired - Lifetime
- 1999-02-03 CA CA2321837A patent/CA2321837C/en not_active Expired - Lifetime
- 1999-02-03 DE DE69936444T patent/DE69936444T3/de not_active Expired - Lifetime
- 1999-02-03 WO PCT/CA1999/000090 patent/WO1999039741A2/en not_active Ceased
- 1999-02-03 AT AT99903557T patent/ATE366121T1/de not_active IP Right Cessation
- 1999-02-03 AU AU24057/99A patent/AU749881B2/en not_active Expired
- 1999-02-03 WO PCT/CA1999/000089 patent/WO1999039740A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999039740A2 (en) | 1999-08-12 |
| AU749881B2 (en) | 2002-07-04 |
| CA2319468A1 (en) | 1999-08-12 |
| DE69936444T2 (de) | 2008-03-20 |
| WO1999039740A3 (en) | 1999-10-28 |
| CA2321837C (en) | 2011-08-16 |
| WO1999039741A2 (en) | 1999-08-12 |
| AU2405799A (en) | 1999-08-23 |
| DE69936444T3 (de) | 2012-05-10 |
| EP1053023A2 (de) | 2000-11-22 |
| CA2321837A1 (en) | 1999-08-12 |
| EP1053023B2 (de) | 2011-03-30 |
| DE69936444D1 (de) | 2007-08-16 |
| JP2002502831A (ja) | 2002-01-29 |
| WO1999039741A3 (en) | 1999-09-30 |
| WO1999039740A9 (en) | 1999-11-25 |
| WO1999039740A8 (en) | 1999-09-23 |
| EP1053023B1 (de) | 2007-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE366121T1 (de) | Systemische verabreichung von serum-stabilen plasmid-lipid partikeln zur krebstherapie | |
| ATE196844T1 (de) | Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten | |
| DE69708100D1 (de) | Konjugate von cis-docosahexaensäure und paclitaxel | |
| AU2592600A (en) | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia | |
| TR199902956T2 (xx) | Pozisyonlar 5 ve 6 i�inde de�i�tirilmi� olan GnRH antagonistleri. | |
| NO985574L (no) | FremgangsmÕter og preparater anvendelige for inhibering av angiogenese | |
| IL134445A0 (en) | A method of preventing or treating estrogen-dependent diseases and disorders | |
| CY2431B1 (en) | Novel phenanthridines substituted in the 6 position. | |
| TW362971B (en) | Pharmaceutical composition and kit for treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and a S-phase or M-phase specific anti | |
| IL141686A0 (en) | Methods of treating hypertension and compositions for use therein | |
| ATE239509T1 (de) | Konjugate zur behandlung von prostatakrebs | |
| BR9912327A (pt) | Inibidores da uroquinase | |
| MXPA04003674A (es) | Uso mejorado de compuesto antitumoral en terapia de cancer. | |
| ATE241993T1 (de) | Zubereitungen zur tumorbehandlung enthaltend hai- knorpelextrakte und antineoplastische mittel | |
| IL146125A0 (en) | Novel quinones as disease therapies | |
| HUP0004326A3 (en) | Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms | |
| CA2259960A1 (en) | Down-regulation of dna repair to enhance sensitivity to p53-mediated suppression | |
| BG103832A (en) | Leptin as tumour cells proliferation inhibitor | |
| EP0944389A4 (de) | Gereinigte zubereitungen von 10-propargyl-10-deazaaminopterin und verfahren zu ihrer verwendung in der tumorbehandlung | |
| IL141550A0 (en) | Methods and compositions for the prevention or treatment of cancer | |
| HUP0302913A3 (en) | Methods of inducing cancer cell death and tumor regression and preparation of pharmaceutical compositions suitable for treating the same | |
| DE69633178D1 (de) | Eisenverbindungen, zusammensetzungen, herstellungsverfahren und verwendungen davon | |
| DE69720783D1 (de) | Reaktive sauerstoffverbindungen enthaltende verbindungen zur induzierung von zelldifferentiation maligner zellen so wie leukämie | |
| ATE258797T1 (de) | Verwendung von amifostin | |
| NO20002804D0 (no) | Konjugater som kan anvendes ved behandling av prostatakreft |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |